{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:03:33Z","timestamp":1794891813542,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The role of recurrence-free survival (RFS) as a validated surrogate endpoint for overall survival (OS) among patients undergoing upfront surgery for intrahepatic cholangiocarcinoma (ICC) has not been defined. We sought to evaluate the correlation between RFS and OS after surgical resection for ICC. We hypothesized that RFS was a reliable surrogate endpoint for OS among patients with ICC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients who underwent upfront curative-intent surgery for ICC between 2000 and 2023 were identified from an international, multi-institutional database. The correlation between RFS and OS was assessed using rank correlation. Landmark analysis evaluated concordance between survival at 5 years and recurrence status at 6, 12, 24, 36, 48, and 54 months postoperatively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 1541 patients who underwent curative-intent hepatic resection, the median RFS and OS were 22.6 months and 41.5 months, respectively. A moderately strong correlation between RFS and OS was identified (<jats:italic>\u03c1<\/jats:italic> = 0.79, 95% CI 0.76 to 0.82). In the landmark analysis, the concordance between 5-year OS after surgery and recurrence status at different time points (6, 12, 24, 36, 48, and 54 months) was 60.7%, 72.0%, 81.4%, 83.1%, 83.0%, and 82.5%, respectively. Restricted cubic spline analysis indicated that the prediction of OS based on RFS increased with time and plateaued 3 years after surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Among patients undergoing curative-intent resection of ICC, there was a moderately strong correlation between RFS and OS. Three-year RFS may be a reliable surrogate endpoint to predict 5-year OS and should be considered in future trial design.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17156-5","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T01:45:38Z","timestamp":1742694338000},"page":"4967-4975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recurrence-Free Survival as a Surrogate for Overall Survival Among Patients with Intrahepatic Cholangiocarcinoma Following Upfront Surgery: An International Multi-institutional Analysis"],"prefix":"10.1245","volume":"32","author":[{"given":"Jun","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selamawit","family":"Woldesenbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujtaba","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Akabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cauchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir","family":"Maithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irinel","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pulitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Aldrighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Poultsides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzzente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas Groot","family":"Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"17156_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00432-010-0971-z","volume":"137","author":"AK Singal","year":"2011","unstructured":"Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma\u2014frequency and demographic patterns: thirty-year data from the MD Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137:1071\u20138. https:\/\/doi.org\/10.1007\/s00432-010-0971-z.","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"17156_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"17156_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-2004-828889","volume":"24","author":"Y Shaib","year":"2004","unstructured":"Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115\u201325. https:\/\/doi.org\/10.1055\/s-2004-828889.","journal-title":"Semin. Liver Dis."},{"issue":"1","key":"17156_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14737140.2022.1999809","volume":"22","author":"DB Hewitt","year":"2022","unstructured":"Hewitt DB, Brown ZJ, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther. 2022;22(1):27\u201338. https:\/\/doi.org\/10.1080\/14737140.2022.1999809.","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"7","key":"17156_CR5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/bjs.10676","volume":"105","author":"XF Zhang","year":"2018","unstructured":"Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848\u201356. https:\/\/doi.org\/10.1002\/bjs.10676.","journal-title":"Br. J. Surg."},{"issue":"9","key":"17156_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","volume":"155","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Sahara K, Wu L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155(9):823\u201331. https:\/\/doi.org\/10.1001\/jamasurg.2020.1973.","journal-title":"JAMA Surg."},{"issue":"5","key":"17156_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol."},{"issue":"10372","key":"17156_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401(10372):195\u2013203. https:\/\/doi.org\/10.1016\/S0140-6736(22)02038-4.","journal-title":"Lancet"},{"issue":"6","key":"17156_CR9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/SLA.0000000000006084","volume":"279","author":"T Imamura","year":"2024","unstructured":"Imamura T, Ohgi K, Mori K, et al. Surrogacy of recurrence-free survival for overall survival as an endpoint of clinical trials of perioperative adjuvant therapy in hepatobiliary-pancreatic cancers: a retrospective study and meta-analysis. Ann Surg. 2024;279(6):1025\u201335. https:\/\/doi.org\/10.1097\/SLA.0000000000006084.","journal-title":"Ann. Surg."},{"issue":"3","key":"17156_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/annonc\/mdv562","volume":"27","author":"ED Saad","year":"2016","unstructured":"Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol. 2016;27(3):373\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdv562.","journal-title":"Ann. Oncol."},{"issue":"2","key":"17156_CR11","doi-asserted-by":"publisher","first-page":"znae038","DOI":"10.1093\/bjs\/znae038","volume":"111","author":"J Okui","year":"2024","unstructured":"Okui J, Nagashima K, Matsuda S, et al. Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. Br J Surg. 2024;111(2):znae038. https:\/\/doi.org\/10.1093\/bjs\/znae038.","journal-title":"Br. J. Surg."},{"issue":"34","key":"17156_CR12","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","volume":"23","author":"DJ Sargent","year":"2005","unstructured":"Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664\u201370. https:\/\/doi.org\/10.1200\/JCO.2005.01.6071.","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"17156_CR13","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/jnci\/djt270","volume":"105","author":"K Oba","year":"2013","unstructured":"Oba K, Paoletti X, Alberts S, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013;105(21):1600\u20137. https:\/\/doi.org\/10.1093\/jnci\/djt270.","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"17156_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/cncr.31154","volume":"124","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, Xie W, Moreira RB, et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer. 2018;124(5):925\u201333. https:\/\/doi.org\/10.1002\/cncr.31154.","journal-title":"Cancer"},{"issue":"7","key":"17156_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","volume":"14","author":"A Mauguen","year":"2013","unstructured":"Mauguen A, Pignon JP, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data. Lancet Oncol. 2013;14(7):619\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(13)70158-X.","journal-title":"Lancet Oncol."},{"key":"17156_CR16","doi-asserted-by":"publisher","unstructured":"Kawashima J, Endo Y, Woldesenbet S, et al. \"Biological R2\" resection for intrahepatic cholangiocarcinoma: identification of patients at risk for poor oncologic outcomes after curative-intent resection.\u00a0HPB (Oxford). Published online January 20, 2025. https:\/\/doi.org\/10.1016\/j.hpb.2025.01.006","DOI":"10.1016\/j.hpb.2025.01.006"},{"issue":"2","key":"17156_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population\u2010based to a more \u201cpersonalized\u201d approach to cancer. CA: A Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA: A Cancer J. Clin."},{"key":"17156_CR18","unstructured":"Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005-. Validity of surrogate endpoints in oncology: Executive summary of rapid report A10-05, Version 1.1. 2011 Nov 21."},{"issue":"8","key":"17156_CR19","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175(8):1389\u201398. https:\/\/doi.org\/10.1001\/jamainternmed.2015.2829.","journal-title":"JAMA Intern. Med."},{"issue":"7","key":"17156_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/bjs\/znad127","volume":"110","author":"K Kataoka","year":"2023","unstructured":"Kataoka K, Takahashi K, Takeuchi J, et al. Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases. Br J Surg. 2023;110(7):864\u20139. https:\/\/doi.org\/10.1093\/bjs\/znad127.","journal-title":"Br. J. Surg."},{"issue":"39","key":"17156_CR21","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.2217\/fon-2023-0098","volume":"19","author":"K Merath","year":"2023","unstructured":"Merath K, Tiwari A, Parikh AA, Pawlik TM. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach. Future Oncol. 2023;19(39):2607\u201321. https:\/\/doi.org\/10.2217\/fon-2023-0098.","journal-title":"Future Oncol."},{"issue":"4","key":"17156_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.21037\/hbsn-2021-12","volume":"10","author":"JM Cloyd","year":"2021","unstructured":"Cloyd JM, Pawlik TM. Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. Hepatobiliary Surg Nutr. 2021;10(4):515\u20137. https:\/\/doi.org\/10.21037\/hbsn-2021-12.","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"2","key":"17156_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.hpb.2022.10.011","volume":"25","author":"Y Endo","year":"2023","unstructured":"Endo Y, Moazzam Z, Alaimo L, et al. Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy. HPB (Oxford). 2023;25(2):229\u201338. https:\/\/doi.org\/10.1016\/j.hpb.2022.10.011.","journal-title":"HPB (Oxford)"},{"issue":"8","key":"17156_CR24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/bjc.2016.83","volume":"114","author":"T Moriwaki","year":"2016","unstructured":"Moriwaki T, Yamamoto Y, Gosho M, et al. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy. Br J Cancer. 2016;114(8):881\u20138. https:\/\/doi.org\/10.1038\/bjc.2016.83.","journal-title":"Br. J. Cancer."},{"issue":"10","key":"17156_CR25","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/S1470-2045(22)00506-X","volume":"23","author":"BL Ecker","year":"2022","unstructured":"Ecker BL, Lee J, Saadat LV, et al. Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. Lancet Oncol. 2022;23(10):1332\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(22)00506-X.","journal-title":"Lancet Oncol."},{"issue":"6","key":"17156_CR26","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1245\/s10434-014-3504-1","volume":"21","author":"M Oba","year":"2014","unstructured":"Oba M, Hasegawa K, Matsuyama Y, et al. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol. 2014;21(6):1817\u201324. https:\/\/doi.org\/10.1245\/s10434-014-3504-1.","journal-title":"Ann. Surg. Oncol."},{"issue":"7","key":"17156_CR27","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1245\/s10434-024-15210-2","volume":"31","author":"DI Tsilimigras","year":"2024","unstructured":"Tsilimigras DI, Endo Y, Guglielmi A, et al. Recurrent intrahepatic cholangiocarcinoma: A 10-point score to predict post-recurrence survival and guide treatment of recurrence. Ann Surg Oncol. 2024;31(7):4427\u201335. https:\/\/doi.org\/10.1245\/s10434-024-15210-2.","journal-title":"Ann. Surg. Oncol."},{"issue":"18","key":"17156_CR28","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40(18):2048\u201357. https:\/\/doi.org\/10.1200\/JCO.21.02568.","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"17156_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192\u2013202. https:\/\/doi.org\/10.1002\/bjs.10776.","journal-title":"Br. J. Surg."},{"issue":"2","key":"17156_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. Jama. 2012;308(2):147\u201356. https:\/\/doi.org\/10.1001\/jama.2012.7352.","journal-title":"Jama"},{"issue":"8","key":"17156_CR31","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","volume":"45","author":"S Yadav","year":"2019","unstructured":"Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol. 2019;45(8):1432\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.023.","journal-title":"Eur. J. Surg. Oncol."},{"issue":"4","key":"17156_CR32","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","volume":"28","author":"O Utuama","year":"2021","unstructured":"Utuama O, Permuth JB, Dagne G, et al. Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease. Ann Surg Oncol. 2021;28(4):1939\u201349. https:\/\/doi.org\/10.1245\/s10434-020-09478-3.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"17156_CR33","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with idh1 mutation: the phase 3 randomized clinical Claridhy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol."},{"issue":"8","key":"17156_CR34","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid."},{"key":"17156_CR35","doi-asserted-by":"publisher","first-page":"1321683","DOI":"10.3389\/fonc.2024.1321683","volume":"14","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Pawlik TM. Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies. Front Oncol. 2024;14:1321683. https:\/\/doi.org\/10.3389\/fonc.2024.1321683.","journal-title":"Front. Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17156-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17156-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17156-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:57:28Z","timestamp":1748869048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17156-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["17156"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17156-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, Mujtaba Khalil, Miho Akabane, Fran\u00e7ois Cauchy, Feng Shen, Shishir Maithel, Irinel Popescu, Minoru Kitago, Matthew J. Weiss, Guillaume Martel, Carlo Pulitano, Luca Aldrighetti, George Poultsides, Andrea Ruzzente, Todd W. Bauer, Ana Gleisner, Hugo Marques, Bas Groot Koerkamp, Itaru Endo, and Timothy M. Pawlik have no conflicts of interest or disclaimers to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}